Q2 2026 13F · SEC CIK 1937964

Artia Global Partners LP

Hedge fundFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value: $526.0M
Reported positions: 47
Top holdings a year, 3 yrs: +16.7%
Assets under management: $778.9M

Artia Global Partners LP is a hedge fund that reported 47 positions worth $526.0M in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Abivax SA (ABVX, 13.1%), Insmed Inc (INSM, 11.9%), Trevi Therapeutics Inc (TRVI, 7.8%). A portfolio copying its top holdings returned 16.7% a year over the last 3 years, against 20.4% for the S&P 500.

Artia Global Partners LP holdings all 47 positions.

Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

Artia Global Partners LP 13F holdings
Stock	% of 13F value	Q1 2026	Shares	Share change	Reported value
ABVXAbivax SA	13.1%	15.1%	516,447	-14.0%	$68.8M
INSMInsmed Inc	11.9%	23.2%	589,052	-6.3%	$62.8M
TRVITrevi Therapeutics Inc	7.8%	5.4%	2,210,852	+9.8%	$41.2M
BTSGBrightspring Health Services I	6.9%	0.5%	517,315	+861.6%	$36.1M
RVMDRevolution Medicines Inc	6.6%	2.7%	185,390	+48.3%	$34.7M
ARGNFArgenx SE	5.2%	4.9%	29,739	+0.0%	$27.6M
ALKSAlkermes PLC	4.5%	New	448,964	—	$23.5M
TVTXTravere Therapeutics Inc	3.7%	0.5%	339,033	+379.5%	$19.3M
AZNAstrazeneca PLC	3.5%	4.2%	98,376	+3.1%	$18.7M
NAMSNewamsterdam Pharma Company Ordinary	3.2%	3.6%	503,936	+0.0%	$17.1M
DNTHDianthus Therapeutics Inc	3.0%	3.1%	162,990	+0.0%	$15.9M
DGXQuest Diagnostics Inc	2.6%	1.8%	65,122	+59.5%	$13.8M
IONSIonis Pharmaceuticals Inc	2.2%	2.4%	144,376	+0.0%	$11.4M
EYPTEyepoint Pharmaceuticals Inc	2.1%	2.2%	767,098	+0.0%	$11.0M
ALMSAlumis Ord	1.5%	1.6%	278,546	-14.3%	$7.8M
VKTXViking Therapeutics Inc	1.3%	1.3%	180,731	+0.0%	$7.1M
CELCCelcuity Inc	1.2%	0.4%	59,316	+280.8%	$6.2M
CYTKCytokinetics	1.1%	0.2%	70,700	+333.7%	$6.0M
MRKMerck & Co Inc	1.1%	1.3%	46,700	+0.0%	$6.0M
RAPPRapport Therapeutics Inc	1.1%	1.0%	138,508	+0.0%	$5.8M
JNJJohnson & Johnson	1.1%	1.2%	22,600	+0.0%	$5.7M
GHGuardant Health Inc	1.1%	New	38,100	—	$5.7M
ABSIAbsci Corporation	1.0%	New	464,444	—	$5.4M
SRRKScholar Rock Hldg Corp	1.0%	1.1%	96,285	+0.0%	$5.3M
829401108Sionna Therapeutics Inc	1.0%	1.1%	119,741	+0.0%	$5.3M
ASNDAscendis Pharma A/s	0.9%	New	17,740	—	$4.7M
ROIVRoivant Sciences Ltd	0.9%	0.8%	129,800	+0.0%	$4.6M
PALIPalisade Bio Inc	0.8%	0.8%	1,992,367	+0.0%	$4.2M
EWTXEdgewise Therapeutics Inc	0.8%	0.5%	98,800	+50.8%	$4.0M
BIIBBiogen Inc	0.8%	0.8%	18,437	+0.0%	$4.0M
XENEXenon Pharmaceuticals Inc	0.7%	0.9%	65,000	+0.0%	$3.9M
BLTEBelite Bio Inc	0.7%	0.9%	24,989	+0.0%	$3.8M
MLYSMineralys Therapeutics Inc	0.7%	0.8%	137,800	+0.0%	$3.7M
PROKProkidney Corp	0.7%	0.7%	1,806,939	+0.0%	$3.7M
ELVNEnliven Therapeutics Inc	0.7%	0.2%	72,100	+245.0%	$3.7M
ORKAOruka Therapeutics Inc	0.6%	New	33,400	—	$3.2M
PTGXProtagonist Therapeutics Inc	0.5%	0.5%	22,951	+0.1%	$2.8M
UTHRUnited Therapeutics Corp Del	0.5%	0.7%	5,000	+0.0%	$2.7M
10919W405Bright Minds Biosciences Inc	0.5%	0.6%	38,407	+0.0%	$2.7M
KNSAKiniksa Pharmaceuticals Intl	0.4%	0.3%	29,200	+0.0%	$1.9M
CMPXCompass Therapeutics Inc	0.2%	New	383,200	—	$839K
PRAXPraxis Precision Medicines I	0.2%	0.2%	2,500	+0.0%	$837K
KODKodiak Sciences Inc	0.1%	0.1%	17,019	+0.0%	$663K
TENXTenax Therapeutics Inc	0.1%	0.2%	42,080	+0.0%	$612K
NUVLNuvalent Inc	0.1%	0.1%	4,900	+0.0%	$605K
PEPGPepgen Inc	0.1%	0.1%	205,324	+0.0%	$370K
SYRESpyre Therapeutics	0.1%	New	4,000	—	$355K

What Artia Global Partners LP bought and sold in Q2 2026, against Q1 2026.

Sold out

Share counts compared with the Q1 2026 13F; a split also changes share counts.

How the holdings did against the S&P 500.

1 year: +19.0% /yr; S&P 500 +20.1%
3 years: +16.7% /yr; S&P 500 +20.4%
5 years: —

A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter	13F value	Positions
Q2 2026	$526.0M	47
Q1 2026	$443.5M	48
Q4 2025	$622.4M	50
Q3 2025	$568.3M	48
Q2 2025	$388.8M	33
Q1 2025	$341.0M	32
Q4 2024	$248.0M	33
Q3 2024	$353.6M	44
Q2 2024	$389.9M	42
Q1 2024	$407.7M	47
Q4 2023	$252.8M	27
Q3 2023	$240.6M	27

Questions about Artia Global Partners LP's portfolio

What stocks does Artia Global Partners LP own?

Artia Global Partners LP's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 47 positions worth $526.0M. The largest are Abivax SA (ABVX) at 13.1%, Insmed Inc (INSM) at 11.9%, Trevi Therapeutics Inc (TRVI) at 7.8%, Brightspring Health Services I (BTSG) at 6.9% and Revolution Medicines Inc (RVMD) at 6.6%.

What did Artia Global Partners LP buy last quarter?

In Q2 2026, Artia Global Partners LP added a new position in Alkermes PLC (ALKS), a new position in Guardant Health Inc (GH), a new position in Absci Corporation (ABSI), a new position in Ascendis Pharma A/s (ASND), a new position in Oruka Therapeutics Inc (ORKA), Brightspring Health Services I (BTSG) (+861.6% shares), Travere Therapeutics Inc (TVTX) (+379.5% shares) and Cytokinetics (CYTK) (+333.7% shares), compared with its Q1 2026 filing.

What did Artia Global Partners LP sell last quarter?

In Q2 2026, Artia Global Partners LP sold all of Eli Lilly & Co (LLY), sold all of Terns Pharmaceuticals Inc (TERN), sold all of Ascendis Pharma A/s, sold all of Abbvie Inc (ABBV), sold all of Soleno Therapeutics Inc (SLNO), Alumis Ord (ALMS) (-14.3% shares), Abivax SA (ABVX) (-14.0% shares) and Insmed Inc (INSM) (-6.3% shares), compared with its Q1 2026 filing.

How has Artia Global Partners LP's portfolio performed?

A portfolio copying Artia Global Partners LP's 20 largest 13F holdings each quarter, from the day each filing was public, returned +16.7% a year over the last 3 years, against +20.4% for the S&P 500. Over 1 year: +19.0% against +20.1%.

When is Artia Global Partners LP's next 13F filing due?

13F filings are due 45 days after each quarter ends. Artia Global Partners LP's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.

How much money does Artia Global Partners LP manage?

Artia Global Partners LP reported $778.9M of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $526.0M.